Ranbaxy, one of India’s largest drugmakers, plans to spin off a research unit devoted to developing original medicines, as part of an effort to expand beyond its core generic drugs business.

A separate research and development business would be more attractive to potential investors and partners, and would lift millions of dollars in expenses from Ranbaxy, the company said on Thursday as it unveiled quarterly results.